BCDA stock forecast
Our latest prediction for BioCardia, Inc.'s stock price was made on the Aug. 2, 2019 when the stock price was at 14.00$.
In the short term (2weeks), BCDA's stock price should outperform the market by 2.77%. During that period the price should oscillate between -9.47% and +14.31%.
In the medium term (3months), BCDA's stock price should underperform the market by -1.81%. During that period the price should oscillate between -16.73% and +25.19%.Get email alerts
Create a solid portfolio with BCDA
About BioCardia, Inc.
BioCardia, Inc. operates as a clinical-stage regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The firm offers proprietary comprehensive biotherapeutic solutions for cardiovascular disease under the CardiAMP and CardiALLO brand. It operates in only one business segment, which is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The company was founded on January 12, 1994 and is headquartered in San Carlos, CA.
At the moment the company generates 1M USD in revenues.
On its last earning announcement, the company reported a loss of -3.15$ per share.
The book value per share is 0.15$
Three months stock forecastAug. 2, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|